Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Cash & Equivalents (2020 - 2025)

Universe Pharmaceuticals' Cash & Equivalents history spans 6 years, with the latest figure at $70.2 million for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 99.76% to $70.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $70.2 million, a 99.76% decrease, with the full-year FY2025 number at $70.2 million, down 99.76% from a year prior.
  • Cash & Equivalents hit $70.2 million in Q3 2025 for Universe Pharmaceuticals, down from $29.5 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for UPC hit a ceiling of $29.5 billion in Q3 2024 and a floor of $5.3 million in Q1 2024.
  • Historically, Cash & Equivalents has averaged $5.1 billion across 5 years, with a median of $39.2 million in 2021.
  • Biggest five-year swings in Cash & Equivalents: surged 70604.67% in 2022 and later plummeted 99.76% in 2025.
  • Tracing UPC's Cash & Equivalents over 5 years: stood at $8.1 million in 2021, then surged by 70604.67% to $5.7 billion in 2022, then dropped by 7.46% to $5.3 billion in 2023, then surged by 458.11% to $29.5 billion in 2024, then plummeted by 99.76% to $70.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for UPC at $70.2 million in Q3 2025, $29.5 billion in Q3 2024, and $5.3 million in Q1 2024.